Oolong tea increases plasma adiponectin levels and low-density lipoprotein particle size in patients with coronary artery disease

Diabetes Research and Clinical Practice

Volumn 65, Issue 3, 2004, Pages 227-234

  Shimada, Kenei ^a   Kawarabayashi, Takahiko ^b   Tanaka, Atsushi ^b   Fukuda, Daiju ^a   Nakamura, Yasuhiro ^a   Yoshiyama, Minoru ^a   Takeuchi, Kazuhide ^a   Sawaki, Tetsuya ^c   Hosoda, Kazuaki ^c   Yoshikawa, Junichi ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Baba Memorial Hospital   (Japan)

^c SUNTORY LTD   (Japan)

Author keywords

Adiponectin; Coronary artery disease; Diabetes mellitus; Oolong tea; Small dense LDL

Indexed keywords

ADIPONECTIN; CAFFEINE; CATECHIN; EPICATECHIN; EPICATECHIN GALLATE; EPIGALLOCATECHIN; EPIGALLOCATECHIN GALLATE; GALLIC ACID; GALLOCATECHIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OOLONG TEA EXTRACT; PLANT EXTRACT; POLYPHENOL DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; WATER;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MALE; PARTICLE SIZE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPONECTIN; BLOOD GLUCOSE; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COLLAGEN; CORONARY DISEASE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PARTICLE SIZE; PROSPECTIVE STUDIES; TEA; TRIGLYCERIDES;

EID: 4344583241     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2004.01.003     Document Type: Article

References (32)

1. Yang C.S., Landau J.M. Effects of tea consumption on nutrition and health. J. Nutr. 130:2000;2409-2412
2. Benzie I.F., Szeto Y.T. Total antioxidant capacity of teas by the ferric reducing/antioxidant power assay. J. Agric. Food Chem. 47:1999;633-636
3. Yang T.T., Koo M.W. Hypercholesterolemic effects of Chinese tea. Pharmacol. Res. 35:1997;505-512
4. Han L.K., Takaku T., Li J., Kimura Y., Okuda H. Anti-obesity action of Oolong tea. Int. J. Obes. Relat. Metab. Disord. 23:1999;98-105
5. Matsuzawa Y., Funahashi T., Nakamura T. Molecular mechanism of metabolic syndrome X: contribution of adipocytokines adipocyte-derived bioactive substances. Ann. N.Y. Acad. Sci. 892:1999;146-154
6. Hotta K., Funahashi T., Arita Y., et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler. Thromb. Vasc. Biol. 20:2000;1595-1599
7. Ouchi N., Kihara S., Arita Y., et al. Novel modulator for endothelial adhesion molecules: adipocyte-derived plasma protein adiponectin. Circulation. 100:1999;2473-2476
8. Okamoto Y., Arita Y., Nishida M., et al. An adipocyte-derived plasma protein, adiponectin, adheres to injured vascular walls. Horm. Metab. Res. 32:2000;47-50
9. Ouchi N., Kihara S., Arita Y., et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation. 103:2001;1057-1063
10. Gardner C.D., Fortmann S.P., Krauss R.M. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 276:1996;875-881
11. Stampfer M.J., Krauss R.M., Ma J., et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 276:1996;882-888
12. Lamarche B., Tchernof A., Mauriege P., et al. Fasting insulin and apolipoprotein B levels and low-density lipoprotein particle size as risk factors for ischemic heart disease. JAMA. 279:1998;1955-1961
13. Griffin B.A., Freeman D.J., Tait G.W., et al. Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) sub-fractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis. 106:1994;241-253
14. The Fifth Report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC V), Arch. Intern. Med. 153 (1993) 154-183.
15. Diabetes mellitus, Report of a WHO Study Group, World Health Organ. Tech. Rep. Ser. 727 (1985) 1-113.
16. Xie B., Shi H., Chen Q., Ho C.T. Antioxidant properties of fractions and polyphenol constituents from green, Oolong and black teas. Proc. Natl. Sci. Counc. 17:1993;77-84
17. Arita Y., Kihara S., Ouchi N., et al. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257:1999;79-83
18. Austin M.A., Breslow J.L., Hennekens C.H., Buring J.E., Willett W.C., Krauss R.M. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 260:1988;1917-1921
19. Ouchi N., Kihara S., Arita Y., et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NF-kappaB signalling through a cAMP-dependent pathway. Circulation. 102:2000;1296-1301
20. Maeda N., Takahashi M., Funahashi T., et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 50:2001;2094-2099
21. Okamoto Y., Kihara S., Ouchi N. Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation. 106:2002;2767-2770
22. Vakkilainen J., Makimattila S., Seppala-Lindroos A. Endothelial dysfunction in men with small LDL particles. Circulation. 102:2000;716-721
23. Chait A., Brazg R.L., Tribble D.L., Krauss R.M. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am. J. Med. 94:1993;350-356
24. Galeano N.F., Milne R., Marcel Y.L., et al. Apoprotein B structure and receptor recognition of triglyceride-rich low density lipoprotein (LDL) is modified in small LDL but not in triglyceride-rich LDL of normal size. J. Biol. Chem. 269:1994;511-519
25. Chen G.C., Liu W., Duchateau P., et al. Conformational differences in human apolipoprotein B-100 among subspecies of low density lipoproteins (LDL). Association of altered proteolytic accessibility with decreased receptor binding of LDL subspecies from hypertriglyceridemic subjects. J. Biol. Chem. 269:1994;2912-2918
26. Anber V., Griffin B.A., McConnell M., Packard C.J., Shepherd J. Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans. Atherosclerosis. 124:1996;261-271
27. Austin M.A., King M.C., Vranizan K.M., Krauss R.M. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation. 82:1990;495-506
28. Reaven G.M., Chen Y.D., Jeppesen J., Maheux P., Krauss R.M. Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles. J. Clin. Invest. 92:1993;141-146
29. Maeda N., Shimomura I., Kishida K., et al. Diet-induced insulin resistance in mice locking adiponectin/ACRP30. Nat. Med. 8:2002;731-737
30. Hotta K., Funahashi T., Bodkin N.L., et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to type 2 diabetes in rhesus monkeys. Diabetes. 50:2001;1126-1133
31. Rumpler W., Seale J., Clevidence B. Oolong tea increases metabolic rate and fat oxidation in men. J. Nutr. 131:2001;2848-2852
32. Miyazaki C., Takeuchi M., Yoshitani H., et al. Optimum hypoglycemic therapy can improve coronary flow velocity reserve in diabetic patients-demonstration by transthoracic Doppler echocardiography. Circ. J. 67:2003;945-950